scholarly journals Double minute amplification of mutant PDGF receptor α in a mouse glioma model

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Hongyan Zou ◽  
Rui Feng ◽  
Yong Huang ◽  
Joseph Tripodi ◽  
Vesna Najfeld ◽  
...  
Keyword(s):  
Pdgf Receptor ◽  
Double Minute ◽  
Glioma Model ◽  
Mouse Glioma

scholarly journals A Syngeneic Mouse Glioma Model for Study of Glioblastoma Therapy

1999 ◽  
Vol 58 (1) ◽  
pp. 54-60 ◽  
Author(s):  
Ned E. Weiner ◽  
Richard B. Pyles ◽  
Claudia L. Chalk ◽  
M Gregory Balko ◽  
Mary Ann Miller ◽  
...  
Keyword(s):  
Syngeneic Mouse ◽  
Glioma Model ◽  
Mouse Glioma

scholarly journals Elevated cellular PpIX potentiates sonodynamic therapy in a mouse glioma stem cell-bearing glioma model by downregulating the Akt/NFkB/MDR1 pathway

2020 ◽  
Author(s):  
Yoshifumi Mizobuchi ◽  
Kenji Shono ◽  
Izumi Yamaguchi ◽  
Kohei Nakajima ◽  
Yuri Fujiwara ◽  
...  
Keyword(s):  
Therapeutic Strategy ◽  
Surgical Intervention ◽  
Aminolevulinic Acid ◽  
Protoporphyrin Ix ◽  
Multidrug Resistant ◽  
Down Regulation ◽  
Sonodynamic Therapy ◽  
Glioma Model ◽  
A Site ◽  
Mouse Glioma

Abstract Glioblastoma (GBM) has high mortality rates because of extremely therapeutic resistance. During surgical resection for GBM, 5-aminolevulinic acid (5-ALA)-induced protoporphyrin IX (PpIX) fluorescence is conventionally applied to distinguish GBM. However, surgical intervention is insufficient for high invasive GBM. Sonodynamic therapy (SDT) is an emerging and promising approach combined with low-intensity ultrasonication (US) and PpIX as a sonosensitizer for cancer, whereas its efficacy is limited. Based on our previous study that down-regulation of multidrug resistant protein (MDR1) in GBM augmented anti-tumor effects of chemotherapy, we hypothesized that elevation of cellular PpIX levels by down-regulation of MDR1 enhances anti-tumor effects by SDT. In high invasive progeny cells from mouse glioma stem cells (GSCs) and a GSC-bearing mouse glioma model, we assessed the anti-tumor effects of SDT with a COX-2 inhibitor, celecoxib. Down-regulation of MDR1 by celecoxib increased cellular PpIX levels, as well as valspodar, a MDR1 inhibitor and augmented anti-tumor effects of SDT. MDR1 down-regulation via Akt/NF-kB pathway by celecoxib was confirmed, using a NF-kB inhibitor, CAPÉ. Thus, elevation of cellar PpIX by down-regulation of MDR1 via Akt/NF-kB pathway may be crucial to potentiate the efficacy of SDT in a site-directed manner and provide a promising new therapeutic strategy for GBM.

MIP-1  Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model

2004 ◽  
Vol 66 (1/2) ◽  
pp. 147-154 ◽  
Author(s):  
Ulrich Herrlinger ◽  
Steffen Aulwurm ◽  
Herwig Strik ◽  
Simone Weit ◽  
Ulrike Naumann ◽  
...  
Keyword(s):  
Gm Csf ◽  
Glioma Model ◽  
Mouse Glioma

Abstract LB-64: Immune modulatory effects of mesenchymal stem cells on regulatory T cells in mouse glioma model

2014 ◽  
Author(s):  
Kyung-Sub Moon ◽  
Derek A. Wainwright ◽  
Irina V. Balyasnikova ◽  
Chung Kwon Kim ◽  
Yoo Seung Ko ◽  
...  
Keyword(s):  
Stem Cells ◽  
T Cells ◽  
Mesenchymal Stem Cells ◽  
Regulatory T Cells ◽  
Glioma Model ◽  
Mouse Glioma

scholarly journals GATA6 is an astrocytoma tumor suppressor gene identified by gene trapping of mouse glioma model

2007 ◽  
Vol 104 (19) ◽  
pp. 8053-8058 ◽  
Author(s):  
D. Kamnasaran ◽  
B. Qian ◽  
C. Hawkins ◽  
W. L. Stanford ◽  
A. Guha
Keyword(s):  
Tumor Suppressor ◽  
Tumor Suppressor Gene ◽  
Suppressor Gene ◽  
Gene Trapping ◽  
Glioma Model ◽  
Mouse Glioma

Investigation of immunosuppressive mechanisms in a mouse glioma model

2009 ◽  
Vol 93 (1) ◽  
pp. 107-114 ◽  
Author(s):  
Alexander Ksendzovsky ◽  
Douglas Feinstein ◽  
Ryan Zengou ◽  
Anthony Sharp ◽  
Paul Polak ◽  
...  
Keyword(s):  
Glioma Model ◽  
Mouse Glioma

Endothelial Wnt/β-catenin signaling reduces vascularization, barrier breakdown and tumor growth in a mouse glioma model

2012 ◽  
Vol 56 (5-6) ◽  
pp. 332
Author(s):  
Marco Reis ◽  
Cathrin J. Czupalla ◽  
Nicole Ziegler ◽  
Kavi Devraj ◽  
Sascha Seidel ◽  
...  
Keyword(s):  
Tumor Growth ◽  
Barrier Breakdown ◽  
Glioma Model ◽  
Mouse Glioma

Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model

2007 ◽  
Vol 106 (4) ◽  
pp. 638-645 ◽  
Author(s):  
Takayuki Amano ◽  
Koji Kajiwara ◽  
Koichi Yoshikawa ◽  
Jun Morioka ◽  
Sadahiro Nomura ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
Therapeutic Potential ◽  
Immunohistochemical Analysis ◽  
Antitumor Effects ◽  
Serological Screening ◽  
Lysosomal Sorting ◽  
Glioma Model ◽  
Vaccination Therapy ◽  
Mouse Glioma

Object The receptor for hyaluronan-mediated motility (RHAMM) is frequently overexpressed in brain tumors and was recently identified as an immunogenic antigen by using serological screening of cDNA expression libraries. In this study, which was conducted using a mouse glioma model, the authors tested the hypothesis that vaccination with dendritic cells transfected with RHAMM mRNA induces strong immunological antitumor effects. Methods The authors constructed a plasmid for transduction of the mRNAs transcribed in vitro into dendritic cells, which were then used to transport the intracellular protein RHAMM efficiently into major histocompatibility complex class II compartments by adding a late endosomal–lysosomal sorting signal to the RHAMM gene. The dendritic cells transfected with this RHAMM mRNA were injected intraperitoneally into the mouse glioma model 3 and 10 days after tumor cell implantation. The antitumor effects of the vaccine were estimated by the survival rate, histological analysis, and immunohistochemical findings for immune cells. Mice in the group treated by vaccination therapy with dendritic cells transfected with RHAMM mRNA survived significantly longer than those in the control groups. Immunohistochemical analysis revealed that greater numbers of T lymphocytes containing T cells activated by CD4+, CD8+, and CD25+ were found in the group vaccinated with dendritic cells transfected with RHAMM mRNA. Conclusions These results demonstrate the therapeutic potential of vaccination with dendritic cells transfected with RHAMM mRNA for the treatment of malignant glioma.

scholarly journals ET-39 * REPEATED PHARMACOLOGICAL DOSES OF ASCORBATE PROTECTS TUMOURS FROM RADIATION DAMAGE IN AN INTRACRANIAL MOUSE GLIOMA MODEL

2014 ◽  
Vol 16 (suppl 5) ◽  
pp. v88-v88
Author(s):  
M. McConnell ◽  
C. Grasso ◽  
M.-S. Fabre ◽  
S. Collis ◽  
L. Castro ◽  
...  
Keyword(s):  
Radiation Damage ◽  
Glioma Model ◽  
Mouse Glioma
Sign in / Sign up

Export Citation Format

Share Document